Dr. Reddy's Laboratories Ltd. (RDY)

39.86
1.10 2.80
NYSE : Health Technology
Prev Close 38.78
Open 39.13
Day Low/High 39.13 / 39.99
52 Wk Low/High 31.69 / 42.82
Volume 116.48K
Avg Volume 188.60K
Exchange NYSE
Shares Outstanding 166.09M
Market Cap 6.36B
EPS 1.60
P/E Ratio 23.60
Div & Yield 0.26 (0.68%)
8 New ETF Gems to Trade

8 New ETF Gems to Trade

Month after month, brand new exchange-traded funds are introduced to the market. Take a look at the recent offerings that offer pure-play exposure to individual emerging market sectors.

5 Winners in Emerging Markets ADRs

5 Winners in Emerging Markets ADRs

While the markets were sliding this week, a handful of emerging markets stocks were turning in gains.

FUJIFILM And Dr. Reddy’s To Establish An Exclusive Joint Venture For Developing, Manufacturing And Promoting Generic Drugs In Japan

FUJIFILM And Dr. Reddy’s To Establish An Exclusive Joint Venture For Developing, Manufacturing And Promoting Generic Drugs In Japan

FUJIFILM Corporation (Head office: Tokyo, Japan) President and CEO, Shigetaka Komori (“Fujifilm” hereinafter) and Dr.

FUJIFILM And Dr. Reddy’s To Establish An Exclusive Joint Venture For Developing, Manufacturing And Promoting Generic Drugs In Japan

FUJIFILM And Dr. Reddy’s To Establish An Exclusive Joint Venture For Developing, Manufacturing And Promoting Generic Drugs In Japan

FUJIFILM Corporation (Head office: Tokyo, Japan) President and CEO, Shigetaka Komori (“Fujifilm” hereinafter) and Dr.

Dr. Reddy’s Announces The Launch Of Gemcitabine For Injection

Dr. Reddy’s Announces The Launch Of Gemcitabine For Injection

Dr. Reddy’s Laboratories (NYSE: RDY) announced today that it has launched Gemcitabine for Injection (200 mg/vial and 1 g/vial), a bioequivalent generic version of Gemzar ®* in the US market on July 25,...

Dr. Reddy’s Acquires Prescription Business Of JB Chemicals & Pharmaceuticals In Russia & Other CIS Markets

Dr. Reddy’s Acquires Prescription Business Of JB Chemicals & Pharmaceuticals In Russia & Other CIS Markets

Dr. Reddy’s Laboratories (NYSE:RDY) announced today that it has entered into an agreement with JB Chemicals & Pharmaceuticals to acquire their pharmaceutical prescription portfolio in the Russia and other CIS ...

Dr. Reddy's Laboratories' CEO Discusses Q1 2012 Results - Earnings Call Transcript

Dr. Reddy's Laboratories' CEO Discusses Q1 2012 Results - Earnings Call Transcript

Dr. Reddy's Laboratories' CEO Discusses Q1 2012 Results - Earnings Call Transcript

Dr. Reddy's Q1 FY12 Financial Results

Dr. Reddy's Q1 FY12 Financial Results

Dr. Reddy’s Laboratories Ltd.

Dr. Reddy’s Announces The USFDA Approval Of Fondaparinux Sodium Injection

Dr. Reddy’s Announces The USFDA Approval Of Fondaparinux Sodium Injection

Dr. Reddy’s Laboratories (NYSE: RDY) and Alchemia Limited, Brisbane, Australia (ASX: ACL) announced today that Dr.

Dr. Reddy's To Release Q1 FY12 Results On July 20, 2011

Dr. Reddy's To Release Q1 FY12 Results On July 20, 2011

Dr. Reddy's Laboratories (NYSE: RDY) will announce results for the First Quarter ended June 30, 2011 on Wednesday, July 20, 2011, after the Board Meeting.

Dr. Reddy’s Announces The Launch Of Levofloxacin Tablets

Dr. Reddy’s Announces The Launch Of Levofloxacin Tablets

Dr. Reddy’s Laboratories (NYSE: RDY) announced today that it has launched Levofloxacin tablets (250 mg, 500 mg and 750 mg), a bioequivalent generic version of LEVAQUIN ®* tablets in the US market on June...

Dr. Reddy Stock To Go Ex-dividend Tomorrow (RDY)

Dr. Reddy Stock To Go Ex-dividend Tomorrow (RDY)

The ex-dividend date for Dr. Reddy Laboratories (NYSE:RDY) is tomorrow, June 14, 2011. Owners of shares as of market close today will be eligible for a dividend of 36 cents per share. At a price of $35 as of 9:31 a.m., the dividend yield is 0.6%.

Dr. Reddy’s Announces Three Generic Product Launches In The US Market

Dr. Reddy’s Announces Three Generic Product Launches In The US Market

Dr. Reddy’s Laboratories (NYSE: RDY) today announced that it has launched the following three products in the US market: Donepezil Hydrochloride tablets (5mg and 10mg strengths), a ...

7 India Stocks With Upside

7 India Stocks With Upside

iGate, ICICI Bank and Patni are expected to deliver up to 49% in the next one year.

Dr. Reddy’s Q4 FY11 & FY11 Financial Results

Dr. Reddy’s Q4 FY11 & FY11 Financial Results

Dr. Reddy’s Laboratories Ltd.

Emerging-Market ADRs: Winners and Losers

Emerging-Market ADRs: Winners and Losers

China's oil and gas stocks and India's banks pulled back sharply at close last week.

Dr. Reddy's To Release Q4 & Full Year FY11 Results On May 13, 2011

Dr. Reddy's To Release Q4 & Full Year FY11 Results On May 13, 2011

Dr. Reddy's Laboratories (NYSE: RDY) will announce results for the Fourth Quarter & Full Year ended March 31, 2011 on Friday, May 13, 2011 after the Board Meeting.

Dr. Reddy Laboratories Ltd. Stock Upgraded (RDY)

Dr. Reddy Laboratories Ltd. Stock Upgraded (RDY)

Dr. Reddy Laboratories (NYSE:RDY) has been upgraded by TheStreet Ratings from a hold to buy.

5 Pharma Stocks That Could Get Squeezed Higher

5 Pharma Stocks That Could Get Squeezed Higher

These heavily shorted pharmaceutical stocks offer potential short-squeeze opportunities.

Dr. Reddy’s Announces The Launch Of Over-the-Counter Fexofenadine HCl Tablets

Dr. Reddy’s Announces The Launch Of Over-the-Counter Fexofenadine HCl Tablets

Dr. Reddy’s Laboratories (NYSE:RDY) announced today that it has launched its over-the-counter (OTC) Fexofenadine HCl tablets on April 13, 2011.

PromiusTM Pharma And Valeant Form Collaboration To Market Cloderm® Cream In The United States

PromiusTM Pharma And Valeant Form Collaboration To Market Cloderm® Cream In The United States

Promius TM Pharma, LLC, an affiliate of Dr. Reddy’s Laboratories (NYSE:RDY), and Valeant Pharmaceuticals International, Inc.

Dr. Reddy’s Announces Completion Of The Acquisition Of US Penicillin Facility And Products From GlaxoSmithKline

Dr. Reddy’s Announces Completion Of The Acquisition Of US Penicillin Facility And Products From GlaxoSmithKline

Dr. Reddy’s Laboratories (NYSE:RDY) today announced the completion of the acquisition of GlaxoSmithKline’s (GSK) United States oral penicillin facility and product portfolio pursuant to the agreement signed and ...

Dr. Reddy’s Launches Levocetirizine Tablets In US

Dr. Reddy’s Launches Levocetirizine Tablets In US

Dr. Reddy’s Laboratories (NYSE:RDY) has launched Levocetirizine tablets (5mg), a bioequivalent generic version of Xyzal® tablets in the US market.

6 Indian Growth Stocks With Upside: Analysts

6 Indian Growth Stocks With Upside: Analysts

HDFC Bank, ICICI Bank and Dr Reddy's are among the Indian stocks that will likely provide an upside up to 31%, according to analysts' estimates.

Dr. Reddy’s Provides Update On The Fexofenadine-Pseudoephedrine 24 Hour Litigation

Dr. Reddy’s Provides Update On The Fexofenadine-Pseudoephedrine 24 Hour Litigation

Dr. Reddy’s Laboratories (NYSE: RDY) announced today that on Friday, 28 January 2011, the U.

Dr. Reddy's Management Discusses Q3 2011 Results - Earnings Call Transcript

Dr. Reddy's Management Discusses Q3 2011 Results - Earnings Call Transcript

Dr. Reddy's Management Discusses Q3 2011 Results - Earnings Call Transcript

Dr. Reddy’s Q3 FY11 Financial Results

Dr. Reddy’s Q3 FY11 Financial Results

Dr. Reddy’s Laboratories Ltd.

5 Drug Stocks With Upside Potential of 25%

5 Drug Stocks With Upside Potential of 25%

These five firms could return 16% to 25% over the next 12 months based on analysts' consensus estimates.

Dr. Reddy's To Release Q3 FY11 Results On January 25, 2011

Dr. Reddy's To Release Q3 FY11 Results On January 25, 2011

Dr. Reddy's Laboratories (NYSE:RDY) will announce results for the Third Quarter ended December 31, 2010 on Tuesday, January 25 th 2011 after the Board Meeting.

TheStreet Quant Rating: B- (Buy)